BackBlack Diamond Therapeutics Overview

Black Diamond Therapeutics Selling, General & Admin

Black Diamond Therapeutics selling, general & admin — quarterly history, peer benchmarks, and growth trends.

Get informed when a big investor buys or sells

+ Follow

Quarterly SG&A Expenses

$4.26M
14.26% YoY

As of Mar 31, 2026

Annual SG&A Expenses (TTM)

$15.86M
38.35% YoY

Trailing 12 months ending Mar 31, 2026

Average SG&A Expenses (Comparison Companies)

Selling, General & Admin History

Selling, General & Admin Comparison

Annual Selling, General & Admin Growth Rate (%)

Annual Selling, General & Admin Growth (Absolute)

Black Diamond Therapeutics (BDTX) FAQ

Stockcircle tracks selling, general & admin for Black Diamond Therapeutics (BDTX), including historical charts and peer comparisons when data is available. Check back as new filings are published, or open the stock overview for a broader fundamental snapshot.

This Selling, General & Admin page is built for Black Diamond Therapeutics's historical SG&A expenses trend and peer context. When enough reporting periods are on file, the charts below visualize how the metric has moved over time.

Use SG&A expenses as one input alongside growth, profitability, valuation, and ownership activity. Stockcircle links related metric pages and the main BDTX overview so you can move from this figure to the surrounding analysis quickly.